

## **THE AMENDMENTS**

### **In the Claims:**

1-10. (Cancelled)

11. (Currently Amended) A method of gene therapy in a ~~non-hepatic~~heart muscle tissue of a patient, comprising delivering to a patient an AAV-2 vector or an AAV particle having a capsid encoded by the AAV-2 vector, wherein the AAV-2 vector carries ~~at least one~~ mutations in a heparin-binding motif of a capsid protein and causes a reduced or eliminated heparin binding function, wherein said mutations ~~is an~~are ~~amino acid substitution at amino acid position arginine R484E and~~amino acid substitution at amino acid position arginine R484E and ~~[[/or]] arginine R585E~~, wherein amino acids R484 and R585 belong to different capsid protein subunits.

12-15. (Cancelled)

16. (Previously Presented) The method of claim 11, wherein the capsid protein is VP1, VP2, or VP3.

17. (Previously Presented) The method of Claim 16, wherein the capsid protein is VP1.

18. (Previously Presented) The method of Claim 11, wherein the amino acid position is numbered according to the numbering based on VP1 protein.

19. (Cancelled)

20. (Previously Presented) The method of claim 11, wherein said delivering is systemic delivering.